The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Treating cancer with microRNA replacement therapy: A literature review
Abstract
microRNAs (miRNAs) are small non‐coding RNAs that regulate gene expression post‐transcriptionally by interfering with the translation of one or more target mRNAs. The unique miRNA sequences are involved in many physiological and pathological processes. Dysregulation of miRNAs contributes to the pathogenesis of all types of cancer. Notably, the diminished expression of tumor suppressor miRNAs, such as members of the Let‐7 and miR‐34 family, promotes tumor progression, invasion and metastasis. The past lustrum in particular, has witnessed substantial improvement of miRNA replacement therapy. This approach aims to restore tumor suppressor miRNA function in tumor cells using synthetic miRNA mimics or miRNA expression plasmids. Here, we provide a comprehensive review of recent advances in miRNA replacement therapy for treatment of cancer and its advantages over conventional gene therapy. We discuss a wide variety of delivery methods and vectors, as well as obstacles that remain to be overcome. Lastly, we review efforts to reverse epigenetic alterations, which affect miRNA expression in cancer cells, and the promising observation that restoring miRNA function re‐sensitizes resistant tumor cells to chemotherapeutic drugs. The fact that various miRNA replacement therapies are currently in clinical trial demonstrates the great potential of this approach to treat cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Wang, F., Xue, X., Wei, J., An, Y., Yao, J. J., Cai, H., Wu, J., Dai, C., Qian, Z., Xu, Z., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605724 · Cited by 135
RetractedKang, L., Mao, J., Tao, Y., Song, B., Ma, W., Lü, Y., Zhao, L., Li, J., Yang, B., & Li, L. (2015) · Cancer Science · doi:10.1111/cas.12656 · Cited by 132
RetractedThe C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Most mammalian mRNAs are conserved targets of microRNAs
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 2×
“It offers the opportunity to silence multiple mRNA targets with a single miRNA or to simultaneously target a single mRNA with several miRNA sequences (Gerlinger et al., 2012).”
BackgroundMicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
The nuclear RNase III Drosha initiates microRNA processing
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Rådmark, O., Kim, S., et al. (2003) · Nature · doi:10.1038/nature01957 · Cited by 5,114
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
miRBase: integrating microRNA annotation and deep-sequencing data
Kozomara, A., & Griffiths-Jones, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1027 · Cited by 3,634
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Causes and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 2×
“While restoration of tumor suppressor gene function effectively reduces tumor growth in mice (Ventura et al., 2007; Xue et al., 2007),”
BackgroundGarzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., & Jones, P. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.020 · Cited by 1,335
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Phylogenetic Shadowing and Computational Identification of Human microRNA Genes
Berezikov, E., Guryev, V., van de Belt, J., Wienholds, E., Plasterk, R. H. A., & Cuppen, E. (2005) · Cell · doi:10.1016/j.cell.2004.12.031 · Cited by 1,270
Doench, J. G., Petersen, C. P., & Sharp, P. A. (2003) · Genes & Development · doi:10.1101/gad.1064703 · Cited by 1,260
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Dendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158
A microRNA DNA methylation signature for human cancer metastasis
Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803055105 · Cited by 1,078
The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., D'Urso, L., Pagliuca, A., Biffoni, M., Labbaye, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1880 · Cited by 989
Chitosan-based formulations for delivery of DNA and siRNA
Mao, S., Sun, W., & Kissel, T. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.08.004 · Cited by 968
Silber, J., Lim, D. A., Petritsch, C., Persson, A. I., Maunakea, A. K., Yu, M., Vandenberg, S. R., Ginzinger, D. G., James, C. D., Costello, J. F., et al. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-14 · Cited by 957
Tazawa, H., Tsuchiya, N., Izumiya, M., & Nakagama, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707351104 · Cited by 903
Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897
Expression profiling identifies microRNA signature in pancreatic cancer
Lee, E. J., Gusev, Y., Jiang, J., Nuovo, G. J., Lerner, M. R., Frankel, W. L., Morgan, D. L., Postier, R. G., Brackett, D. J., & Schmittgen, T. D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22394 · Cited by 896
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
p53 represses c-Myc through induction of the tumor suppressor miR-145
Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., Elble, R., Watabe, K., & Mo, Y.-Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808042106 · Cited by 841
Kunath, K. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00076-2 · Cited by 809
microRNAs in cancer management
Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70073-6 · Cited by 734
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells
Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., Xiang, D., DeSano, J. T., Bommer, G. T., Fan, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006816 · Cited by 689
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0655 · Cited by 677
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
let-7 MicroRNA Functions as a Potential Growth Suppressor in Human Colon Cancer Cells
Akao, Y., Nakagawa, Y., & Naoe, T. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.903 · Cited by 619
The Promise of MicroRNA Replacement Therapy
Bader, A. G., Brown, D., & Winkler, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2010 · Cited by 617
Su, H., Yang, J.-R., Xu, T., Huang, J., Xu, L., Yuan, Y., & Zhuang, S.-M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2886 · Cited by 612
Toyota, M., Suzuki, H., Sasaki, Y., Maruyama, R., Imai, K., Shinomura, Y., & Tokino, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0325 · Cited by 600
The let-7 microRNA reduces tumor growth in mouse models of lung cancer
Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., Weidhaas, J. B., Brown, D., Bader, A. G., & Slack, F. J. (2008) · Cell Cycle · doi:10.4161/cc.7.6.5834 · Cited by 593
Godlewski, J., Nowicki, M. O., Bronisz, A., Williams, S., Otsuki, A., Nuovo, G., RayChaudhury, A., Newton, H. B., Chiocca, E. A., & Lawler, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2629 · Cited by 587
Tsai, W.-C., Hsu, P. W.-C., Lai, T.-C., Chau, G.-Y., Lin, C.-W., Chen, C.-M., Lin, C.-D., Liao, Y.-L., Wang, J.-L., Chau, Y.-P., et al. (2009) · Hepatology · doi:10.1002/hep.22806 · Cited by 583
Effects of Microrna-29 on Apoptosis, Tumorigenicity, and Prognosis of Hepatocellular Carcinoma
Xiong, Y., Fang, J.-H., Yun, J.-P., Yang, J., Zhang, Y., Jia, W.-H., & Zhuang, S.-M. (2010) · Hepatology · doi:10.1002/hep.23380 · Cited by 563
microRNAs join the p53 network — another piece in the tumour-suppression puzzle
He, L., He, X., Lowe, S. W., & Hannon, G. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2232 · Cited by 547
Anand, S., Majeti, B. K., Acevedo, L. M., Murphy, E. A., Mukthavaram, R., Scheppke, L., Huang, M., Shields, D. J., Lindquist, J. N., Lapinski, P. E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2186 · Cited by 517
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
Regression of murine lung tumors by the let-7 microRNA
Trang, P., Medina, P. P., Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Homer, R., Brown, D., Bader, A. G., Weidhaas, J. B., et al. (2010) · Oncogene · doi:10.1038/onc.2009.445 · Cited by 500
Bai, S., Nasser, M. W., Wang, B., Hsu, S.-H., Datta, J., Kutay, H., Yadav, A., Nuovo, G., Kumar, P., & Ghoshal, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.016774 · Cited by 477
New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites
Lee, I., Ajay, S. S., Yook, J. I., Kim, H. S., Hong, S. H., Kim, N. H., Dhanasekaran, S. M., Chinnaiyan, A. M., & Athey, B. D. (2009) · Genome Research · doi:10.1101/gr.089367.108 · Cited by 476
CD44, a therapeutic target for metastasising tumours
Orian-Rousseau, V. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.024 · Cited by 474
First microRNA mimic enters clinic
Bouchie, A. (2013) · Nature Biotechnology · doi:10.1038/nbt0713-577 · Cited by 472
Tolia, N. H., & Joshua-Tor, L. (2007) · Nature Chemical Biology · doi:10.1038/nchembio848 · Cited by 461
Zhu, H., Wu, H., Liu, X., Evans, B. R., Medina, D. J., Liu, C.-G., & Yang, J.-M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.007 · Cited by 456
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Takeshita, F., Patrawala, L., Osaki, M., Takahashi, R.-U., Yamamoto, Y., Kosaka, N., Kawamata, M., Kelnar, K., Bader, A. G., Brown, D., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.207 · Cited by 420
MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma
Ibrahim, A. F., Weirauch, U., Thomas, M., Grünweller, A., Hartmann, R. K., & Aigner, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4645 · Cited by 400
Smart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer Therapy
Choi, K. Y., Yoon, H. Y., Kim, J.-H., Bae, S. M., Park, R.-W., Kang, Y. M., Kim, I.-S., Kwon, I. C., Choi, K., Jeong, S. Y., et al. (2011) · ACS Nano · doi:10.1021/nn202070n · Cited by 399
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
Ji, Q., Hao, X., Meng, Y., Zhang, M., DeSano, J., Fan, D., & Xu, L. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-266 · Cited by 394
Broderick, J. A., & Zamore, P. D. (2011) · Gene Therapy · doi:10.1038/gt.2011.50 · Cited by 388
Bandi, N., Zbinden, S., Gugger, M., Arnold, M., Kocher, V., Hasan, L., Kappeler, A., Brunner, T., & Vassella, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4277 · Cited by 386
MicroRNA control of muscle development and disease
Williams, A. H., Liu, N., van Rooij, E., & Olson, E. N. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.029 · Cited by 350
Cancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346
Developing therapeutic microRNAs for cancer
Bader, A. G., Brown, D., Stoudemire, J., & Lammers, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.79 · Cited by 333
Liang, Z., Wu, H., Xia, J., Li, Y., Zhang, Y., Huang, K., Wagar, N., Yoon, Y., Cho, H. T., Scala, S., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.10.017 · Cited by 330
miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer
Yu, S., Lu, Z., Liu, C., Meng, Y., Ma, Y., Zhao, W., Liu, J., Yu, J., & Chen, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4531 · Cited by 328
Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules
Vigderman, L., & Zubarev, E. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.004 · Cited by 305
Diabetes mellitus, a microRNA-related disease?
Guay, C., Roggli, E., Nesca, V., Jacovetti, C., & Regazzi, R. (2011) · Translational Research · doi:10.1016/j.trsl.2011.01.009 · Cited by 300
miR-126 functions as a tumour suppressor in human gastric cancer
Feng, R., Chen, X., Yu, Y., Su, L., Yu, B., Li, J., Cai, Q., Yan, M., Liu, B., & Zhu, Z. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.06.004 · Cited by 291
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J. J. B., Vallely, M. P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt412 · Cited by 275
Osaki, M., Takeshita, F., Sugimoto, Y., Kosaka, N., Yamamoto, Y., Yoshioka, Y., Kobayashi, E., Yamada, T., Kawai, A., Inoue, T., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.53 · Cited by 271
Role of anti-oncomirs miR-143 and -145 in human colorectal tumors
Akao, Y., Nakagawa, Y., Hirata, I., Iio, A., Itoh, T., Kojima, K., Nakashima, R., Kitade, Y., & Naoe, T. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.88 · Cited by 262
Dong, Q., Meng, P., Wang, T., Qin, W., Qin, W., Wang, F., Yuan, J., Chen, Z., Yang, A., & Wang, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010147 · Cited by 245
Kasinski, A. L., & Slack, F. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2001 · Cited by 242
Small RNA combination therapy for lung cancer
Xue, W., Dahlman, J. E., Tammela, T., Khan, O. F., Sood, S., Dave, A., Cai, W., Chirino, L. M., Yang, G. R., Bronson, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412686111 · Cited by 242
Tivnan, A., Orr, W. S., Gubala, V., Nooney, R., Williams, D. E., McDonagh, C., Prenter, S., Harvey, H., Domingo-Fernández, R., Bray, I. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038129 · Cited by 233
miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc
Chen, Z., Zeng, H., Guo, Y., Liu, P., Pan, H., Deng, A., & Hu, J. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-151 · Cited by 230
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer
Wu, Y., Crawford, M., Mao, Y., Lee, R. J., Davis, I. C., Elton, T. S., Lee, L. J., & Nana-Sinkam, S. P. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.14 · Cited by 223
Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2010) · The Prostate · doi:10.1002/pros.21185 · Cited by 205
Therapeutic potential for microRNAs
Esau, C. C., & Monia, B. P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.007 · Cited by 195
Huang, X., Schwind, S., Yu, B., Santhanam, R., Wang, H., Hoellerbauer, P., Mims, A., Klisovic, R., Walker, A. R., Chan, K. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3191 · Cited by 193
Zhou, K., Nguyen, L. H., Miller, J. B., Yan, Y., Kos, P., Xiong, H., Li, L., Hao, J., Minnig, J. T., Zhu, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520756113 · Cited by 183
miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7
Sun, Y., Bai, Y., Zhang, F., Wang, Y., Guo, Y., & Guo, L. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.098 · Cited by 182
MicroRNA dysregulation in psychiatric disease
Miller, B. H., & Wahlestedt, C. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.035 · Cited by 180
Qiu, T., Zhou, X., Wang, J., Du, Y., Xu, J., Huang, Z., Zhu, W., Shu, Y., & Liu, P. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.054 · Cited by 177
MiRNA-451 plays a role as tumor suppressor in human glioma cells
Nan, Y., Han, L., Zhang, A., Wang, G., Jia, Z., Yang, Y., Yue, X., Pu, P., Zhong, Y., & Kang, C. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.074 · Cited by 176
Yang, H.-W., Huang, C.-Y., Lin, C.-W., Liu, H.-L., Huang, C.-W., Liao, S.-S., Chen, P.-Y., Lu, Y.-J., Wei, K.-C., & Ma, C.-C. M. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.057 · Cited by 172
MicroRNA Delivery by Cationic Lipoplexes for Lung Cancer Therapy
Wu, Y., Crawford, M., Yu, B., Mao, Y., Nana-Sinkam, S. P., & Lee, L. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2002076 · Cited by 172
Formulation of poly(d,l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery
Tinsley-Bown, A. M., Fretwell, R., Dowsett, A. B., Davis, S. L., & Farrar, G. H. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00275-8 · Cited by 166
MicroRNA-145 Targets YES and STAT1 in Colon Cancer Cells
Gregersen, L. H., Jacobsen, A. B., Frankel, L. B., Wen, J., Krogh, A., & Lund, A. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008836 · Cited by 164
Lan, F., Wang, H., Chen, Y., Chan, C., Ng, S. S., Li, K., Xie, D., He, M., Lin, M. C., & Kung, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.25336 · Cited by 163
Torrisani, J., Bournet, B., du Rieu, M. C., Bouisson, M., Souque, A., Escourrou, J. R., Buscail, L., & Cordelier, P. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.134 · Cited by 160
Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma
Cosco, D., Cilurzo, F., Maiuolo, J., Federico, C., Martino, M. T. D., Cristiano, M. C., Tassone, P., Fresta, M., & Paolino, D. (2015) · Scientific Reports · doi:10.1038/srep17579 · Cited by 155
miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells
Noonan, E. J., Place, R. F., Basak, S., Pookot, D., & Li, L. (2010) · Oncotarget · doi:10.18632/oncotarget.167 · Cited by 149
Stahlhut, C. E., & Slack, F. J. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1003008 · Cited by 148
Piao, L., Zhang, M., Datta, J., Xie, X., Su, T., Li, H., Teknos, T. N., & Pan, Q. (2012) · Molecular Therapy · doi:10.1038/mt.2012.67 · Cited by 146
Chiou, G., Cherng, J., Hsu, H., Wang, M., Tsai, C., Lu, K., Chien, Y., Hung, S., Chen, Y., Wong, C.-I., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.014 · Cited by 146
Bian, H., Pan, X., Yang, J., Wang, Z.-X., & De, W. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-20 · Cited by 144
Biomaterials for Gene Delivery Atelocollagen-mediated Controlled Release of Molecular Medicines
Ochiya, T., Nagahara, S., Sano, A., Itoh, H., & Terada, M. (2001) · Current Gene Therapy · doi:10.2174/1566523013348887 · Cited by 142
Gaur, S., Wen, Y., Song, J. H., Parikh, N. U., Mangala, L. S., Blessing, A. M., Ivan, C., Wu, S. Y., Varkaris, A. S., Shi, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4971 · Cited by 138
Roth, J. A. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.1.55 · Cited by 131
Yoo, B. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh516 · Cited by 116
Dailey, L. A., Wittmar, M., & Kissel, T. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.003 · Cited by 108
Kitade, Y., & Akao, Y. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10r12fm · Cited by 105
MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer
Luo, Q., Li, X., Li, J., KONG, X., Zhang, J., Chen, L., Huang, Y., & Fang, L. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2034 · Cited by 103
Role of microRNAs in stem/progenitor cells and cardiovascular repair
Jakob, P., & Landmesser, U. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr311 · Cited by 101
Takei, Y., Takigahira, M., Mihara, K., Tarumi, Y., & Yanagihara, K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2530 · Cited by 100
Ekin, A., Karataş, Ö. F., Çulha, M., & Özen, M. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2810 · Cited by 97
Wang, X., Yu, B., Ren, W., Mo, X. M., Zhou, C., He, H., Jia, H., Wang, L., Jacob, S. T., Lee, R. J., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.027 · Cited by 95
Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma
Cioce, M., Ganci, F., Canu, V., Sacconi, A., Mori, F., Canino, C., Korita, E., Casini, B., Alessandrini, G., Cambria, A., et al. (2013) · Oncogene · doi:10.1038/onc.2013.476 · Cited by 88
MicroRNA-503 and the Extended MicroRNA-16 Family in Angiogenesis
Caporali, A., & Emanueli, C. (2011) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.05.003 · Cited by 87
Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo
Luwor, R. B., Baradaran, B., Taylor, L. E., Iaria, J., Nheu, T. V., Amiry, N., Hovens, C. M., Wang, B., Kaye, A. H., & Zhu, H.-J. (2012) · Oncogene · doi:10.1038/onc.2012.260 · Cited by 82
Self-citationControlled delivery of antisense oligonucleotides: a brief review of current strategies
Zhao, X., Pan, F., Holt, C. M., Lewis, A. L., & Lu, J. R. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902992894 · Cited by 82
Wang, H., Zhao, X., Guo, C., Ren, D., Zhao, Y., Xiao, W. L., & Jiao, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139136 · Cited by 79
Zhao, H., Fan, W., Hao, J., Wu, X., Zeng, G. Q., Zhang, L., Nie, S. F., & Wang, X. D. (2014) · Drug Delivery · doi:10.3109/10717544.2014.920059 · Cited by 76
Innovative Strategy for MicroRNA Delivery in Human Mesenchymal Stem Cells via Magnetic Nanoparticles
Schade, A., Delyagina, E., Scharfenberg, D., Skorska, A., Lux, C. A., David, R., & Steinhoff, G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140610710 · Cited by 76
Cancer complexity slows quest for cure
Hayden, E. C. (2008) · Nature · doi:10.1038/455148a · Cited by 74
Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer
Liu, J. (2009) · Oncology Reports · doi:10.3892/or_00000554 · Cited by 74
Jiang, Y., Tang, G., Zhang, L.-H., Kong, S.-Y., Zhu, S., & Pei, Y. (2010) · Journal of drug targeting · doi:10.3109/10611860903494203 · Cited by 72
Liang, G., Zhu, Y., Jing, A., Wang, J., Hu, F., Feng, W., Xiao, Z., & Chen, B. (2016) · Gene Therapy · doi:10.1038/gt.2016.60 · Cited by 72
Instability of miRNA and cDNAs derivatives in RNA preparations
Bravo-Egaña, V., Rosero, S., Ricordi, C., & Pastori, R. L. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.135 · Cited by 68
Bakhshandeh, B., Soleimani, M., Hafizi, M., & Ghaemi, N. (2012) · Cytotechnology · doi:10.1007/s10616-012-9430-9 · Cited by 51
Hatakeyama, H., Murata, M., Sato, Y., Takahashi, M. M., Minakawa, N., Matsuda, A., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.023 · Cited by 44
Synthetic Pre-miRNA-Based shRNA as Potent RNAi Triggers
Terasawa, K., Shimizu, K., & Tsujimoto, G. (2011) · Journal of Nucleic Acids · doi:10.4061/2011/131579 · Cited by 42
In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells
Kaban, K., Şalva, E., & Akbuğa, J. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0633 · Cited by 39
Wu, W., Liu, S., Liang, Y., Zhou, Z., & Liu, X. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0386-x · Cited by 28
Kaban, K., Şalva, E., & Akbuğa, J. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.030 · Cited by 26
Łabieniec-Watała, M., Karolczak, K., Siewiera, K., & Watała, C. W. (2013) · Molecules · doi:10.3390/molecules181113769 · Cited by 23
MiR-15a suppresses hepatocarcinoma cell migration and invasion by directly targeting cMyb.
Liu, B., Sun, T., Wu, G., Shang-Guan, H., Zj, J., Zhang, J.-R., & Zheng, Y. (2017) · Europe PMC (PubMed Central) · Cited by 17
Cited by
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Zhang, L., Liao, Y., & Tang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1059-5 · Cited by 510
Epidrugs: targeting epigenetic marks in cancer treatment
Miranda Furtado, C. L., Dos Santos Luciano, M. C., Silva Santos, R. D., Furtado, G. P., Moraes, M. O., & Pessoa, C. (2019) · Epigenetics · doi:10.1080/15592294.2019.1640546 · Cited by 345
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Self-citationmiRNAs as therapeutic tools and biomarkers for prostate cancer
Arrighetti, N., & Beretta, G. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030380 · Cited by 43
Metadata
- Authors
- Hosseinahli, N., Aghapour, M., Duijf, P. H. G., & Baradaran, B.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-03-09
- Volume
- 233
- Issue
- 8
- Pages
- 5574-5588
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2792995236
- Cited by
- 305
- References
- 136
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.